Satellos Bioscience Inc Com V.ICO

RE:Targeted Markets iCo-007 - Diabetes-Related Blindness ~$3B+.

[allain250]

Conclusion It’s been a very long time, if ever, since I’ve come across a stock with as much blue sky potential as iCo Therapeutics. Great management, obviously on side with shareholders, tight share structure, confirmation from others about the effectiveness of their products and a socially responsible investment that in my opinion makes one feel good about investing. That’s hard to beat. iCo’s share price is presently very cheap for a company in this sector. But with conference season starting and news from three drugs starting to flow soon I don’t expect the stock to stay long at present price levels.